The agency wants applicants to demystify their algorithms and provide specific details about what the models do, how they’re ...

Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and ...

A University of Exeter funding scheme designed to combat the global challenge of fungal antimicrobial resistance (fAMR) has announced a new call for applications.

Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...

CNW/ -- (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth ...

Inhibition of group IVA cytosolic phospholipase A2 (cPLA2α) is a potential approach for cancer treatment. Here, the authors report thiazolyl ketone inhibitors of cPLA2α starting from compound ...

Artificial intelligence (AI) is transforming the health care landscape, from diagnostics to drug development and clinical trials. As AI ...

The FDA published its first draft guidance on the use of AI in the development of drugs and biological products ...

Now, in 2025, we expect the life sciences industry will scale its use of GenAI with greater purpose. As these applications ...